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Background: The Elecsys hepatitis B surface antigen (HBsAg) II quantitative assay is a newly 
introduced electrochemiluminescence immunoassay incorporating an initial 1:400 onboard 
dilution and a simple algorithm to determine HBsAg levels in serum. We evaluated the 
performance of the Elecsys HBsAg II assay and determined the impact of its initial onboard 
dilution on laboratory efficiency.
Methods: HBsAg levels were determined using both Roche Elecsys and Abbott Architect 
HBsAg assays. Linearity and precision of the Elecsys HBsAg II assay and its correlation 
with the Architect HBsAg assay were evaluated. In particular, precision was verified at 
Samsung Medical Center, Severance Hospital, Seoul St. Mary's Hospital in Seoul, using the 
same pooled serum controls. The efficiency of the dilution algorithm for both methods was 
verified using data from 1,848 clinical samples.
Results: The Elecsys HBsAg II assay showed a good linearity from 0.1 to 48,000.0 IU/mL and 
a good correlation (r=0.9998) between expected and measured values. Precision analyses 
performed at Samsung Medical Center, Severance Hospital, Seoul St. Mary's Hospital showed 
excellent performance with coefficients of variation between 1.28% and 6.82%. The values of 
the Elecsys HBsAg II and Architect HBsAg assays were well correlated (n=506, r=0.987, P
＜0.001) and also reliably determined in hepatitis C virus- and hepatitis B virus-co-infected 
patient sera (n=27). In terms of efficiency, 64.0% of samples provided a final HBsAg result 
on the first run without the need for further dilution, when using the 1:400 onboard pre-
dilution protocol of the Elecsys HBsAg II assay.
Conclusions: Given the excellent precision and correlation with the Architect assay, the 
Elecsys HBsAg II assay showed a potential advantage for laboratory efficiency by significantly 
reducing the need for retesting samples with high HBsAg levels.
(J Lab Med Qual Assur 2014;36:196-204)
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INTRODUCTION
The quantification of hepatitis B surface antigen 
(HBsAg) and hepatitis B virus (HBV) DNA levels is 
expected to play an important role in predicting and 
evaluating antiviral therapy responses in patients with 
chronic HBV hepatitis [1,2]. Recent studies suggested 
that the slow kinetics of covalently closed circular DNA 
(cccDNA) under powerful antiretroviral treatment is a 
main cause of viral rebound after interruption of long-
term therapy [3,4]. Serum HBsAg is a marker that can 
predict the presence of cccDNA in a simple way without 
invasive liver biopsy, because serum HBsAg quantification 
in patients with chronic hepatitis B permits a good 
correlation with hepatocyte nuclear cccDNA levels. In 
patients with low viral loads, hepatocellular carcinoma 
(HCC) risk is determined by levels of HBsAg, alanine 
aminotransferase, and age, but not HBV DNA [5].
Currently, two fully automated HBsAg assays are 
co mmercially available: the Architect HBsAg assay 
(Abbott Diagnostics, Abbott Park, IL, USA) and the 
Elecsys HBsAg II (Roche Diagnostics, Indianapolis, IN, 
USA). The earlier developed Architect HBsAg assay 
is predominantly optimised for low-level detection and 
does not fully meet the requirements of follow-up under 
a laboratory perspective. Evaluation studies with clinical 
samples revealed varying values of HBsAg depending on 
infection phases. The immune-tolerant phase presented 
the highest median HBsAg levels, ranging from 4.5 to 
5.0 log10 IU/mL, and even an extremely high level of up 
to 6.0 log10 IU/mL has been reported [6-9]. The Elecsys 
HBsAg II is a new quantitative electrochemiluminescence 
immunoassay, incorporating an initial 1:400 onboard 
dilution and a simple algorithm to determine HBsAg levels 
in serum. This may allow for the majority of samples from 
actively HBV infected patients to be measured without 
further manual dilution, thereby facilitating laboratory 
automation.
Here, we aimed to evaluate (1) the precision of HBsAg 
quantification results in clinical laboratories of Samsung 
Medical Center, Severance Hospital, Seoul St. Mary's 
Hospital in Seoul, (2) the correlation between the Roche 
Elecsys HBsAg II quantitative assay and the Abbott 
Architect assay as applied to patients with HBV infection, 
and (3) the efficiency of the onboard dilution algorithm of 
the Roche Elecsys HBsAg II assay under the perspective 
of laboratory workload at Samsung Medical Center.
MATERIALS AND METHODS
1. Subjects and Controls
This evaluation study was conducted from August to 
September 2011 at Samsung Medical Center, Severance 
Hospital, Seoul St. Mary's Hospital in Seoul, Korea. 
Control sera used for the performance evaluation were 
produced at Samsung Medical Center and distributed 
to Severance Hospital, Seoul St. Mary's Hospital under 
identical conditions. For linearity assessment, pooled sera 
containing 43,654 IU/mL were diluted with normal sera. 
Pooled sera with low, medium and high levels of HBsAg, 
predetermined by the Abbott Architect HBsAg reagent 
kit, were used as control samples for precision analyses. 
From 31 August to 26 September 2011, sera used for 
the correlation analysis of the two assays were randomly 
selected from the samples requesting HBsAg analysis at 
the Division of Hepatology of Samsung Medical Center.
The 1,848 results of HBsAg quantification by the Abbott 
Architect assay were archived retrospectively, in order 
to assess the efficiency of the onboard dilution algorithm 
of the Roche Elecsys HBsAg II assay. Those results 
were generated from the samples mainly requested by 
the Division of Hepatology of Samsung Medical Center 
between 1 August and 30 September 2011. Clinical 
samples enrolled in correlation assessment were from 
patients with chronic hepatitis B, liver cirrhosis, and 
HCC. The 386 patients consisted of 253 males (66%) 
and 133 females (34%). Mean age was 54 years with a 
standard deviation of 12 years. HBV infection phase and 
disease stage data were only available from Samsung 
Medical Center. This study was carried out with the 
approval of the institutional review board of Samsung 
Medical Center (2011-06-088).
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2. Performance Evaluation Protocol
Linearity and precision of the Elecsys HBsAg II assays 
were verified using the pooled control sera according 
to the Clinical and Laboratory Standards Institute 
(CLSI) guidelines. For precision, repeatability and total 
imprecision evaluation (according to EP05-A2), the 
center A: Samsung Medical Center, center B: Severance 
Hospital, center C: Seoul St. Mary's Hospital used the 
same study protocol and control materials, which were 
distributed to each laboratory as multiple frozen aliquots 
so that they would be thawed only once before analysis. 
The linearity of dilution recovery (according to EP06-A), 
using control materials, and the correlation of the Elecsys 
HBsAg II assay with the Abbott Architect HBsAg assay 
using clinical samples (according to CLSI EP09-A2) were 
evaluated at Samsung Medical Center. The efficiency of 
the onboard dilution algorithm was verified by simulation 
of the proportion of samples at the final HBsAg levels that 
were generated without retesting in the Roche Elecsys 
HBsAg II assay, using retrospective test results of the 
Abbott Architect HBsAg assay.
3. Quantification of Hepatitis B Surface Antigen
HBsAg levels were determined using the quantitative 
Elecsys HBsAg II and Abbott Architect HBsAg assays. 
The Elecsys HBsAg II assay is an in vitro diagnostic elec-
trochemiluminescence immunoassay for the quantification 
of HBsAg in human serum and plasma using the 
sandwich principle on the Modular Analytics E170, cobas 
e 601 and cobas e 602 analysers. An initial 1:400 onboard 
dilution is mandatory for every sample, as described 
in Fig. 1. If the result for a 400-fold diluted sample 
falls within 20 to 52,000 IU/mL, no further dilution is 
necessary and an endpoint result is achieved. If a result 
falls below the above-mentioned range, the sample has to 
be re-run undiluted and should return 0.05 to 130 IU/mL. 
If a result returns ＞52,000 IU/mL for a 400-fold diluted 
sample, further manual dilution steps are recommended 
until results fall into the clinically relevant ranges. To 
evaluate this dilution procedure, a series of manual 
dilutions were performed for each sample.
The Abbott Architect HBsAg assay is a two-step im-
munoassay, using chemiluminescent microparticle im-
munoassay technology for the quantitative determination 
of HBsAg in human serum and plasma. A specimen 
with a concentration greater than or equal to 0.05 IU/
mL is considered reactive for HBsAg. If the HBsAg value 
exceeds 250 IU/mL, repeated measurement of the HBsAg 
level, using 1:500 manually or automatically diluted 
specimens, is recommended. The dilution algorithm of the 
Roche Elecsys HBsAg II assay is described in Fig. 1, along 
with that of the Abbott Architect HBsAg assay.
4. Data Analysis
The respective dilution factor was used to calculate the 
final HBsAg level from the obtained measurement values 
of samples. In order to guarantee that our results would 
not be biased by outliers from undetectable levels, all 
values of ＜0.05 IU/mL were imputed as zero (n=78).
For precision analysis, the mean, SD, and CV were 
given at each HBsAg level. Linear regression and 
Pearson correlation analysis were used to establish the 
relationship between the two methods. Bland-Altman 
plots were generated to determine the limits of agreement 
for the comparison between the two sets of data, using the 
Elecsys assay as the dependent variable and the Architect 
Roche Elecsys
1:400 dilution
Abbott
Undiluted
IU/mL
20 52,000 IU/mL <20 IU/mL >52,000 IU/mL <250 IU/mL >250 IU/mL
IU/mL
Report
Retest
undiluted
and report
Retest 1:20
dilution and
report x20
Report
Retest 1:500
dilution and
x500report
Fig. 1. Onboard dilution algorithm 
of Roche Elecsys, in comparison with 
Abbott Architect.
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assay as the independent variable.
RESULTS
1. Linearity and Precision Assessment of Roche Elecsys 
   Hepatitis B Surface Antigen II Quantitative Assay
The Elecsys HBsAg II assay showed linearity from 0.1 
to 48,000.0 IU/mL and a good correlation (r=0.9998, 
r2=0.9997) between measured and expected values (Fig. 
2). Precision analyses performed at the Samsung Medical 
Center, Severance Hospital, Seoul St. Mary's Hospital 
with control samples ranging from 65.11 to 19,569.26 IU/
mL showed excellent performance with coefficients of 
variation between 1.28% and 6.82% (Table 1).
2. Correlation between Results of the Roche Elecsys 
   Hepatitis B Surface Antigen II Quantitative Assay and 
   the Abbott Architect Hepatitis B Surface Antigen Assay
A total of 386 serum samples from 386 patients were 
included in the analysis. The agreement of positive and 
negative results between the two assays was 99.5% 
(384/386); two negative results of the Abbott Architect 
were positive in the Roche Elecsys assay. As shown in 
Fig. 3, there was an excellent correlation between the 
HBsAg values determined by the two assays (correlation 
coefficient r=0.987, P＜0.001), and differences between 
their results were expressed by a Bland-Altman plot 
(mean, 70.8; 95% confidence interval, -1,158.8 to 1,300.4). 
In addition, HBsAg levels were reliably determined in 
HCV- and HBV-co-infected patient sera (n=27). 
3. Assessment of the Efficiency of the Mandatory 
Onboard Dilution Algorithm
For the simulation of the workload of the Roche Elecsys 
HBsAg II assay with mandatory onboard dilution of 
specimens, 1,848 retrospective test results of the Abbott 
Architect HBsAg assay, acquired from patients mainly 
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Fig. 2. Linearity by dilutional recovery.
Table 1. Precision of hepatitis B surface antigen measurement in a multi-center setting
Instrument Material Mean
Imprecision SD (CV%)
Between-day Between-run Within-run Total
Center A Modular analytics E170
Low 71.19 2.63 (3.69) 2.98 (4.19) 1.75 (2.45) 3.26 (4.58)
Medium 1,665.39 58.44 (3.51) 65.90 (3.96) 32.18 (1.93) 70.5 (4.23)
High 18,836.72 794.60 (4.22) 870.78 (4.62) 421.63 (2.24) 931.4 (4.94)
Center B Modular analytics E170
Low 65.11 1.34 (2.06) 1.81 (2.78) 1.23 (1.89) 2.02 (3.10)
Medium 1,568.43 26.02 (1.66) 36.53 (2.33) 38.61 (2.46) 45.82 (2.92)
High 18,999.43 933.92 (4.90) 1,247.31 (6.56) 465.44 (2.44) 1,300.38 (6.82)
Center C Cobas 6000
Low 73.37 0.94 (1.28) 2.17 (2.96) 1.20 (1.63) 2.35 (3.19)
Medium 1,671.75 34.59 (2.06) 50.50 (3.02) 30.92 (1.84) 55.60 (3.31)
High 19,569.26 417.95 (2.13) 626.94 (3.20) 363.95 (1.85) 687.47 (3.50)
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referred by the Division of Hepatology, were included. By 
using 1:400 pre-dilution of samples, final HBsAg levels 
could be determined in 64.0% of the samples (1,183/1,848) 
during the first run. In other words, 36.0% of clinical 
samples required further dilution or no dilution in the 
Roche Elecsys HBsAg II quantitative assay, while 52.9% 
of samples had to be analysed repeatedly to determine 
final HBsAg levels in the Abbott Architect HBsAg assay, 
using no initial pre-dilution protocol (Fig. 4).
DISCUSSION
HBsAg is the oldest but clearest marker of both acute 
and chronic HBV infection [10]. Traditionally, the clinical 
use of HBsAg had been limited to qualitative assays. 
While quantification of HBsAg was introduced twenty 
years ago, it reached clinical significance only recently, 
when newly developed quantitation reagents were adopted 
in automated analysers. 
Quantification of serum HBsAg is an emerging bio-
marker for prognosis and treatment response in chronic 
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Fig. 3. (A) Correlation of Roche Elecsys (y axis) and Abbott 
Architect (x axis) quantitative HBs Ag assays, expressed by linear 
scale (left) and logarithm scale (right) (95% confidence interval 
for r, 0.9844 to 0.9895; P<0.001), (B) Difference between Elecsys 
and Abbott Architect quantitative HBs Ag assays expressed by 
Bland-Altman plot (mean 70.8; 95% confidence interval, -1158.8 
to 1300.4), mean difference (solid line), +/-2SD (dotted lines).
Fig. 4. Impact of dilution algorithm affecting laboratory 
efficiency.
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hepatitis B [11] and can predict cccDNA in a simple 
way without invasive liver biopsy. cccDNA resides in an 
infected hepatocyte nucleus as a stable, resistant, and 
enduring non-integrated minichromosome, acting as a 
template for the transcription of viral genes and being 
responsible for viral persistence. Therefore, the challenge 
of antiviral therapy for chronic hepatitis B is to clear the 
liver of cccDNA. HBsAg levels should theoretically reflect 
the amount of total cccDNA in the liver as well as its 
transcriptional activity. A positive correlation between 
HBsAg levels, serum HBV DNA, and liver cccDNA has 
been noted in most studies of HBsAg-positive patients 
[12,13].
As values of HBsAg quantification can range from 0 to 
6.0 log10 IU/mL in clinical samples [6-9], any quantitative 
assay is required to be reproducible between 0 and 
extremely high levels. As the earlier developed Abbott 
Architect HBsAg assay is predominantly optimised for 
low-level detection, not fully meeting the requirements 
of follow-up under a laboratory perspective, specimens 
with an HBsAg value exceeding 250 IU/mL are flagged 
with the code ‘＞250.00 IU/mL’ and need to be diluted 
up to 1:500, using a manual dilution procedure. Before 
the recent arrival of an Architect assay that includes 
automatic onboard dilution for designated specimens, the 
manual dilution procedure was the main weakness of this 
assay.
Several recent studies indicated that the newly intro-
duced Roche Elecsys HBsAg II quantitative assay showed 
favourable performance and good correlation with the 
established Abbott Architect HBsAg assay [8,14-19]. 
Here, we also revealed that the Roche Elecsys HBsAg II 
quantitative assay, as used at Samsung Medical Center, 
Severance Hospital, Seoul St. Mary's Hospital in Korea, 
showed good performance in linearity and precision.
Our study confirms previous results using a research 
protocol for the quantification of HBsAg based on the 
quantitative Elecsys HBsAg II assay that also correlated 
well with the Abbott Architect assay. As its clinical use 
continues to be defined and elaborated, it is likely that 
HBsAg quantification will become an established part of 
patient management.
In addition, the treatment of co-infections by HBV 
and other viruses such as HIV and HCV has clinical 
implications in association with the immune status [20-
22]. A previous study showed that the Elecsys assay is 
fully capable of quantifying serum HBsAg levels in HIV-
HBV-co-infected patients, with very high correlation and 
precision compared to the Architect assay [8]. In that 
study, the authors described no substantial difference 
between methods in HIV-HBV-co-infected patients 
with HCV-positive and HCV-negative serology. The 
present study also shows that HBsAg levels were reliably 
determined in HCV-HBV-co-infected patients.
As described above, HBsAg levels can be as high as 
4.5 to 5.0 log10 IU/mL in clinical samples [6-9]. The 
onboard dilution algorithm is one of the key benefits of 
the Elecsys HBsAg II quantitative assay, minimising the 
need for retesting samples with high amounts of HBsAg 
that exceed the actual measurement range of the test 
reagent. Our data showed that 1,183 of 1,848 samples 
(64.0%) tested using the 1:400 onboard dilution algorithm 
returned a final HBsAg result on the first run without the 
need of further dilution. On the other hand, the Architect 
HBsAg assay needed further dilution in 52.9% of clinical 
samples after initial undiluted measurement.
These results were mainly derived from both inpatients 
and outpatients visiting the Division of Hepatology. The 
efficiency of the clinical laboratory was increased by using 
the onboard dilution algorithm of the Elecsys HBsAg II 
assay, as the proportion of samples from HBV infected 
patients was relatively large. Considering the necessity of 
additional runs of the Roche Elecsys HBsAg II assay with 
undiluted sera of negative or low level samples (＜20 IU/
mL), it would be prudent to apply this assay selectively 
for HBV-infected patients, found with a qualitative 
HBsAg assay, in order to magnify the efficiency of the 
onboard dilution system. Otherwise, testing efficiency 
may deteriorate. Above all, to make the best use of the 
clinical significance of HBsAg levels, quantitative assays 
may be preferentially used in hepatitis-oriented hospitals 
and clinics, based on antiviral therapeutic approaches. 
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In conclusion, the Elecsys HBsAg II assay correlated 
excellently with another commercially available HBsAg 
quantitative assay, and its mandatory onboard dilution 
algorithm added the additional advantage of the pre-
dilution protocol, particularly useful under specific 
conditions such as the analysis of specimens from a 
hepatitis clinic or known hepatitis patients by reducing 
repeated measurements and increasing laboratory 
efficiency.
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Elecsys B형 간염 바이러스 표면항원 정량검사의 장비 내 희
석 알고리즘에 의한 검사 효율성 향상
손지연1,2,* • 오은지3 • 김현숙4 • 박형두2 • 강은숙2
1국립암센터 진단검사의학과, 2성균관대학교 의과대학 삼성서울병원 진단검사의학과, 3가톨릭대학교 의과대학 
서울성모병원 진단검사의학과, 4연세대학교 의과대학 세브란스병원 진단검사의학과
*이전 소속기관
배경: Elecsys HBsAg II 정량검사는 비교적 최근에 도입된 분석법으로서, 분석 첫 단계부터 내장 
1:400 희석을 적용하여 혈청 HBs 항원의 농도를 측정하는 알고리즘을 이용한다. Elecsys HBsAg II 
정량검사의 성능을 평가하고, 초기 내장 희석법이 검사실 효율성에 미치는 영향을 분석하였다.
방법: Elecsys 및 Architect HBsAg 정량검사로 HBs 항원의 양을 측정하였다. Elecsys HBsAg II 정량
검사의 직선성과 정밀도 및 Architect HBsAg 정량검사와의 상관성을 평가하였다. 정밀도는 대한민
국 서울의 삼성서울병원, 세브란스병원, 서울성모병원에서 동일한 혈청 검체를 사용하여 검증하였
다. 위 두 가지 정량검사법의 희석 알고리즘의 효율성은 1,848개의 임상 검체 결과를 이용하여 검
증하였다.
결과: Elecsys HBsAg II 정량검사는 0.1-48,000.0 IU/mL 농도 범위에서 예상치 및 측정치간 양호한 
직선성을 나타내었다(r=0.9998). 세 개 기관에서 시행된 정밀도 평가에서 변이계수는 1.28-6.82%
로 매우 우수하였다. Elecsys HBsAg II 및 Architect HBs Ag 정량 수치는 상관성이 매우 우수하였으
며 (n=506, r=0.987, P＜0.001), 이는 HCV와 HBV 동시감염 환자의 혈청에서도 확인하였다(n=27). 
효율성 평가에서, Elecsys HBsAg II 정량검사의 내장 1:400 희석법을 이용하였을 때 전체 검체 중 
64.0%는 추가 희석과정 없이 최종 HBs 항원 정량 수치를 보고할 수 있는 것으로 추산되었다.
결론: Elecsys HBsAg II 정량검사는 정밀도가 매우 우수하고 기존 Architect 정량검사와의 상관성이 
높음이 증명되었으며, 초기 HBs 항원의 농도가 높은 검체를 희석하여 재검할 필요성을 현저히 줄
임으로써 검사실 효율성을 높이는 데 기여할 수 있음을 확인하였다.
(J Lab Med Qual Assur 2014;36:196-204)
교신저자: 강은숙
우)135-710 서울시 강남구 일원로 81, 성균관대학교 의과대학 삼성서울병원 진단검사의학과
Tel: 02)3410-2703, Fax: 02)3410-2719, E-mail: eskang@skku.edu
